Concord Drugs
65.38
+1.17(+1.82%)
Market Cap₹64.20 Cr
PE Ratio151.44
IndustryHealthcare
Company Performance:
1D+1.82%
1M-4.62%
6M+112.76%
1Y+74.35%
5Y+155.89%
View Company Insightsright
Latest news about Concord Drugs
Concord Drugs Reports 31% Revenue Growth and Quadrupled Profit in Q1 Aug 08, 2025
Concord Drugs Limited reported robust Q1 financial results. Consolidated revenue reached Rs 1,360.64 crore, up 31% quarter-on-quarter and 16.4% year-on-year. Net profit surged to Rs 11.77 crore, a threefold increase from the previous quarter and more than fourfold from the same period last year. Standalone revenue was Rs 1,338.35 crore with Rs 11.14 crore net profit. The company's subsidiary, Proton Remedies Private Limited, contributed Rs 40.44 crore to revenue and Rs 0.62 crore to profit. Basic EPS improved to Rs 0.12, and the company reported no loan defaults.
Concord Drugs to Hold Board Meeting on Fundraising Initiatives Jun 30, 2025